Psyence Biomedical Ltd. (PBM) Stock

About Psyence Biomedical Ltd.

Psyence Biomedical Ltd. is led by CEO Jody Aufrichtig, employs 12 people, headquartered in CA, publicly traded since 2021.

Psyence Biomedical Ltd. (PBM) stock trades at $4.17 with a market capitalization of $79214. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.41, reflecting a net loss over the last twelve months, price-to-book of 0.17, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.92 and $175.78, and currently trades 97.6% below its 52-week high.

On profitability, Psyence Biomedical Ltd. generates a return on equity (ROE) of -58.62% (negative, reflecting a net loss), return on capital employed of -36.81%.

Psyence Biomedical Ltd. by the numbers, 2020–2025

Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-7.0M in 2025.

On a trailing twelve-month basis to Sep '25, revenue is $0 and net profit $-27.0M.

Borrowings stand at $0, cash from operations was $-8.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged 88.7% over five years, and was -41.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Psyence Biomedical Ltd. (PBM) — frequently asked questions